Biomea Fusion Inc Market Cap ($45.10 Million)
Market Cap & Net Worth: Biomea Fusion Inc (BMEA)
Biomea Fusion Inc market cap. Biomea Fusion Inc (NASDAQ:BMEA) has a market capitalization of $45.10 Million ($45.10 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22095 globally and #4925 in its home market, demonstrating a -1.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biomea Fusion Inc's stock price $0.62 by its total outstanding shares 72299440 (72.30 Million). Also see cash flow conversion of Biomea Fusion Inc for how efficiently the company converts equity into cash flow.
Biomea Fusion Inc Market Cap History (2021–2026)
Biomea Fusion Inc market cap history from 2021 to 2026. Data shows change from $538.63 Million to $45.10 Million (-45.74% CAGR). Check Biomea Fusion Inc stock quote for real-time trading data and today's change.
Index Memberships
Biomea Fusion Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #630 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2090 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.00% | #247 of 263 |
Weight: Biomea Fusion Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biomea Fusion Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biomea Fusion Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BMEA net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BMEA by Market Capitalization
Companies near Biomea Fusion Inc in the global market cap rankings as of November 5, 2026. Also see Biomea Fusion Inc assets under control for a full breakdown of the balance sheet.
Key companies related to Biomea Fusion Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Biomea Fusion Inc (2021–2026)
Market capitalization of Biomea Fusion Inc from 2021 to today. Between 2021 and today, Biomea Fusion Inc's market cap moved from $538.63 Million to $ 45.10 Million, with a yearly change of -45.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $45.10 Million | -49.69% |
| 2025 | $89.65 Million | -68.04% |
| 2024 | $280.52 Million | -73.28% |
| 2023 | $1.05 Billion | +72.24% |
| 2022 | $609.48 Million | +13.15% |
| 2021 | $538.63 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Biomea Fusion Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.10 Million USD |
| MoneyControl | $45.10 Million USD |
| MarketWatch | $45.10 Million USD |
| marketcap.company | $45.10 Million USD |
| Reuters | $45.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase I… Read more